However, T-DM1 demonstrated poor activity for early BC with low and/or heterogeneous HER2 expression in the neoadjuvant setting [61], further reinforcing the view that only HER2 overexpressing tumors are HER2 pathway-dependent and therefore benefit from HER2-directed therapy. The gene discussed is ERBB2; the disease is breast cancer.